scholarly journals Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials

Thorax ◽  
2004 ◽  
Vol 59 (9) ◽  
pp. 777-782 ◽  
Author(s):  
G V Robinson
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Obstructive Sleep Apnoea ◽  
Randomised Controlled Trials ◽  
Sleep Apnoea ◽  
Controlled Trials ◽  
Obstructive Sleep ◽  
Randomised Controlled

scholarly journals Morbidity and mortality in patients with cardiovascular risk factors and obstructive sleep apnoea: results from the DIAST-CHF cohort

2019 ◽  
Vol 154 ◽  
pp. 127-132 ◽  
Author(s):  
Helge Haarmann ◽  
Jennifer Koch ◽  
Nina Bonsch ◽  
Meinhard Mende ◽  
Stefanie Maria Werhahn ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Obstructive Sleep Apnoea ◽  
Sleep Apnoea ◽  
Morbidity And Mortality ◽  
Obstructive Sleep

scholarly journals Cardiovascular risk factors in men and women with obstructive sleep apnoea syndrome

2010 ◽  
Vol 104 (7) ◽  
pp. 1063-1068 ◽  
Author(s):  
Jean-Pierre Laaban ◽  
Line Mounier ◽  
Olivier Roque d'Orbcastel ◽  
Dan Veale ◽  
Jacques Blacher ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Obstructive Sleep Apnoea ◽  
Sleep Apnoea ◽  
Obstructive Sleep Apnoea Syndrome ◽  
Men And Women ◽  
Sleep Apnoea Syndrome ◽  
Obstructive Sleep

Obstructive sleep apnoea, type 2 diabetes and cardiovascular risk factors

2017 ◽  
Vol 39 ◽  
pp. e16-e17 ◽  
Author(s):  
B. De Vega Sánchez ◽  
S.A. Juarros Martínez ◽  
Milagros Del Olmo Chiches ◽  
C. Disdier Vicente ◽  
E. González Sarmiento
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Obstructive Sleep Apnoea ◽  
Sleep Apnoea ◽  
Obstructive Sleep

Endocrine responses during CPAP withdrawal in obstructive sleep apnoea: data from two randomised controlled trials

Thorax ◽  
2019 ◽  
Vol 74 (11) ◽  
pp. 1102-1105
Author(s):  
Sira Thiel ◽  
Sarah R Haile ◽  
Mirko Peitzsch ◽  
Esther I Schwarz ◽  
Noriane A Sievi ◽  
...  
Keyword(s):  
Obstructive Sleep Apnoea ◽  
Randomised Controlled Trials ◽  
Sleep Apnoea ◽  
Controlled Trials ◽  
Short Term ◽  
Link Type ◽  
Obstructive Sleep ◽  
Cardiometabolic Markers ◽  
Randomised Controlled ◽  
Pituitary Adrenal Axis

The aim of this investigation was to elucidate the effect of CPAP withdrawal on neurometabolic and cardiometabolic markers in patients with obstructive sleep apnoea. We evaluated 70 patients (mean age 61±10 years, 82% men) treated with CPAP in two 2-week, parallel, randomised controlled trials. CPAP withdrawal resulted in elevated 3,4-dihydroxyphenylglycol, norepinephrine and cortisol after 2 weeks of CPAP withdrawal; however, no statistically significant changes of the renin–angiotensin–aldosterone system (RAAS) determinants were documented. In summary, CPAP withdrawal may be more prominently linked to short-term increases in sympathetic activation than hypothalamic–pituitary–adrenal axis or RAAS activation. ClinicalTrials.gov Identifier: NCT02493673 and NCT02050425.

scholarly journals Coexistence of cardiovascular risk factors and obstructive sleep apnoea in polysomnography

2021 ◽  
pp. 103782
Author(s):  
Paweł Gać ◽  
Dominika Urbanik ◽  
Piotr Macek ◽  
Helena Martynowicz ◽  
Grzegorz Mazur ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Obstructive Sleep Apnoea ◽  
Sleep Apnoea ◽  
Obstructive Sleep

scholarly journals Non-sleepy obstructive sleep apnoea: to treat or not to treat?

2019 ◽  
Vol 28 (154) ◽  
pp. 190031 ◽  
Author(s):  
Nejat Altintas ◽  
Renata L. Riha
Keyword(s):  
Quality Of Life ◽  
Obstructive Sleep Apnoea ◽  
Randomised Controlled Trials ◽  
Sleep Apnoea ◽  
Controlled Trials ◽  
Obstructive Sleep ◽  
Randomised Controlled ◽  
Industrialised Countries

Non-sleepy obstructive sleep apnoea (OSA) is thought to have a prevalence of around 20–25% in industrialised countries. However, the question of whether it should be routinely treated or not is controversial. This review collates the results from recent randomised controlled trials addressing OSA and examines whether treating the condition leads to improvements in quality of life and reduced cardiometabolic dysfunction, comorbidities generally attributed to untreated obstructive sleep apnoea/hypopnoea syndrome.

Sign in / Sign up

Export Citation Format

Share Document